Detalhe da pesquisa
1.
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Breast Cancer Res
; 21(1): 90, 2019 08 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31391067
2.
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
Breast Cancer Res Treat
; 168(2): 413-420, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29230665
3.
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
Breast Cancer Res Treat
; 171(1): 65-74, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29766362
4.
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(9): 1211-1220, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28732650
5.
70-Gene Signature in Early-Stage Breast Cancer.
N Engl J Med
; 375(22): 2199, 2016 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27959763
6.
Tumor-expressed factor VII is associated with survival and regulates tumor progression in breast cancer.
Blood Adv
; 7(11): 2388-2400, 2023 06 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36920782
7.
Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer.
Oncogene
; 41(48): 5176-5185, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36271029
8.
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
J Clin Oncol
; 38(28): 3273-3281, 2020 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32706636
9.
Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer.
Mol Cancer Ther
; 19(2): 680-689, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31727690
10.
Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?
Eur J Cancer
; 89: 1-8, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29223019
11.
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Eur J Cancer
; 95: 59-67, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29635145
12.
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
J Natl Cancer Inst
; 110(1)2018 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28922787
13.
Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Oncotarget
; 8(9): 15610-15620, 2017 Feb 28.
Artigo
Inglês
| MEDLINE | ID: mdl-28121628
14.
Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.
Clin Med Insights Oncol
; 7: 41-51, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23471238